Global Phosphodiesterase-4 (PDE-4) Inhibitors Market To Reach $3,450 Million By 2025

(MENAFN- Market Press Release) July 14, 2025 4:07 am - The Phosphodiesterase-4 (PDE-4) inhibitors market is growing due to increasing prevalence of inflammatory diseases like COPD, psoriasis, and atopic dermatitis.

Growing prevalence of chronic respiratory and dermatological conditions propels PDE-4 inhibitor adoption; market projected to grow at 8% CAGR through 2032.

The global Phosphodiesterase-4 (PDE-4) Inhibitors market is poised to reach $3,450 million by 2025, expanding steadily at a compound annual growth rate (CAGR) of 8% from 2025 to 2032. This growth is fueled by increasing therapeutic use in treating chronic obstructive pulmonary disease (COPD), psoriasis, and atopic dermatitis. North America currently leads market contributions, while Asia Pacific is expected to register the fastest growth due to expanding healthcare access and rising disease awareness.

Request for customization

Respiratory and Dermatological Applications at the Forefront

Demand for PDE-4 inhibitors is especially strong in the respiratory care segment, with roflumilast being widely prescribed for managing severe COPD. Dermatological applications, including treatments for plaque psoriasis and eczema, are also gaining momentum with the growing adoption of topical PDE-4 inhibitors like crisaborole. Increased clinical research around neurological and autoimmune disorders suggests future expansion into additional therapeutic areas.

Price Trends See Moderate Growth Amid Rising Demand

The average global price for PDE-4 inhibitors rose by approximately 4% between 2024 and 2025, with notable increases in the United States and Germany, driven by heightened demand and regulatory shifts favoring novel anti-inflammatory drugs. In contrast, countries like India have seen price stabilization due to generic competition and local manufacturing incentives. Future price trajectories will likely reflect a balance between innovation-driven costs and competitive pressure from biosimilars and generics.

Global Leaders Driving Innovation and Market Penetration

Key players shaping the PDE-4 inhibitors market include Amgen Inc. and Pfizer Inc. in North America, Almirall S.A. and LEO Pharma A/S in Europe, and Cipla Ltd. in Asia. These companies are investing in R&D to expand indications and improve drug delivery formats. Strategic collaborations, pipeline development, and regional market expansions remain critical tactics among leading firms to maintain a competitive edge in this rapidly evolving sector.

MENAFN14072025003520003262ID1109798083